Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following Zynquista Setbacks

Strategic Restructuring:
Lexicon Pharmaceuticals has announced a strategic restructuring to eliminate its commercial operations and focus on clinical development following FDA's deficiency letter regarding Zynquista[1][2].

Workforce Reduction:
The company will reduce its workforce by approximately 60% by December 31st, 2024, to preserve cash and focus on advancing its clinical development pipeline[1][2].

Cost Savings:
The restructuring is expected to reduce 2025 operating costs by $100 million, in addition to previously announced $40 million savings[1][2].

R&D Pipeline Focus:
Lexicon will prioritize its R&D pipeline, including the Phase 2b PROGRESS study of LX9211 for diabetic peripheral neuropathic pain, the Phase 3 SONATA HCM study of sotagliflozin, and IND-enabling studies of LX9851 for obesity[1][2].

Zynquista Setbacks:
The FDA's "deficiencies preclude discussion" letter for Zynquista represents a major setback in the type 1 diabetes and CKD space, leading to the strategic shift[1][2].

INPEFA Availability:
INPEFA will continue to be available but without promotional efforts, as the company focuses on its clinical development pipeline[1][2].